Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $77.50 short call and a strike $82.50 long call offers a potential 104.08% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $77.50 by expiration. The full premium credit of $2.55 would be kept by the premium seller. The risk of $2.45 would be incurred if the stock rose above the $82.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is at 33.25 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
3 Big Biotech Stocks Poised for More Declines
Wed, 28 Mar 2018 17:06:00 +0000
Biogen, Gilead and Amgen Inc. have fallen so far that they now look like they might be bargains.
Is Gilead Sciences a Beaten-Up Biotech Stock to Buy?
Tue, 27 Mar 2018 23:15:00 +0000
There are reasons for optimism, but headwinds remain.
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
Tue, 27 Mar 2018 12:01:49 +0000
Gilead Sciences Inc NASDAQ/NGS:GILD
Facebook stock was tanking today even before the FTC investigation news hit the wires
Mon, 26 Mar 2018 17:39:32 +0000
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves in the mega-cap tech giants.
3 Blockbuster Drug Launches to Watch In 2018
Mon, 26 Mar 2018 11:47:00 +0000
A disappointing performance from one of these new drugs hitting the market right now could spell disaster for these stocks. Here's what to look for.
Also on Market Tamer…
Follow Us on Facebook